| Literature DB >> 35155824 |
Akihisa Tatsumi1, Shinya Maekawa1, Leona Osawa1, Ryo Katoh1, Yasuyuki Komiyama1, Natsuko Nakakuki1, Hitomi Takada1, Shuya Matsuda1, Masaru Muraoka1, Yuichiro Suzuki1, Mitsuaki Sato1, Ei Takahashi1, Mika Miura1, Fumitake Amemiya1, Shinichi Takano1, Mitsuharu Fukasawa1, Tatsuya Yamaguchi1, Yasuhiro Nakayama1, Taisuke Inoue1, Hiroki Okada2, Takuji Araki2, Hiroshi Onishi2, Nobuyuki Enomoto1.
Abstract
BACKGROUND AND AIM: Recently, balloon-occluded retrograde transvenous obliteration (BRTO), performed for spontaneous portosystemic shunts (SPSS), has been receiving attention as a measure to improve liver function in cirrhotic patients with portal hypertension. However, it is unclear whether SPSS diameter is associated with changes in hepatic venous pressure gradient (HVPG) and liver function after BRTO.Entities:
Keywords: balloon‐occluded retrograde transvenous obliteration; hepatic venous pressure gradient; liver function; spontaneous portosystemic shunt diameter
Year: 2022 PMID: 35155824 PMCID: PMC8829100 DOI: 10.1002/jgh3.12712
Source DB: PubMed Journal: JGH Open ISSN: 2397-9070
Backgrounds of the patients
| Factors |
|
|---|---|
| Median age, years (range) | 66.5 (44–85) |
| Sex (male/female) | 18/16 |
| Etiology (HBV/HCV/alcohol plus HCV/alcohol/PBC/NASH/unknown) | 3/16/3/4/2/2/4 |
| Indication of BRTO (GV/HE) | 18/16 |
| Child–Pugh (A/B/C) | 7/19/8 |
| History of HCC, | 15 (44.1%) |
| Median observation period, days (range) | 1182 (224–5141) |
| Liver‐related death, | 17 (50%) |
BRTO, balloon‐occluded retrograde transvenous obliteration; GV, gastric varices; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HE, hepatic encephalopathy; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cholangitis.
Characteristics of the patients classified by Child–Pugh scores
| Characteristics | All | Child–Pugh score |
| ||
|---|---|---|---|---|---|
| A | B | C | |||
|
|
|
|
| ||
| Median age, years (range) | 66.5 (44–85) | 69 (61–76) | 71 (47–85) | 58.5 (44–78) | 0.125 |
| Sex (male/female) | 18/16 | 1/6 | 9/8 | 7/1 | 0.018 |
| Indication of BRTO (GV/HE) | 18/16 | 7/0 | 10/9 | 1/7 | 0.003 |
| History of HCC, | 15 (44.1%) | 1 (11%) | 11 (64%) | 3 (38%) | 0.003 |
| Alb (g/dL), median (range) | 3.3 (1.8–4.3) | 3.7 (3.4–4.3) | 3.3 (2.5–4.2) | 2.3 (1.8–3.1) | 0.004 |
| T‐Bil (mg/dL), median (range) | 1.2 (0.3–5.6) | 1.3 (0.6–2.4) | 1.0 (0.3–2.3) | 2.1 (0.5–5.6) | 0.050 |
| AST (U/L), median (range) | 47 (14–138) | 32 (14–91) | 45 (14–138) | 58 (36–82) | 0.438 |
| ALT (U/L), median (range) | 27 (11–106) | 26 (17–73) | 29 (11–106) | 25 (13–65) | 0.807 |
| Plt (×10−4/μL), median (range) | 8.2 (3.1–26.2) | 9.6 (4.3–14.6) | 8.3 (3.1–26.2) | 7.2 (5.4–16.9) | 0.830 |
| PT (%), median (range) | 66 (27–91) | 78 (50–91) | 66 (53–91) | 57 (27–68) | 0.033 |
| NH3 (μL/dL), median (range) | 104 (42–249) | 66 (42–104) | 104 (42–238) | 123 (94–249) | 0.015 |
| Diameter of shunt (mm), median (range) | 15 (6–35) | 11 (6–18) | 13 (7–32) | 22 (18–35) | < 0.001 |
P < 0.05,
P < 0.01.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BRTO, balloon‐occluded retrograde transvenous obliteration; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; GV, gastric varices; PT, prothrombin time.
Figure 1Changes in clinical parameters 6 months after balloon‐occluded retrograde transvenous obliteration (BRTO) in 34 patients. (a) Changes in serum albumin (Alb), prothrombin time (PT, %), and NH3. (b) Changes in total bilirubin, FIB‐4 index, and Child–Pugh (CP) score. Significant improvements in albumin (P = 0.001), PT (P = 0.001), blood ammonia (P = 0.001), and CP score (P < 0.001) were observed 6 months after BRTO. Total bilirubin showed a tendency to decrease (P = 0.241), while no improvement was evident in FIB‐4 (P = 0.497). *P < 0.05, **P < 0.01.
Characteristics of the patients, classified by spontaneous portosystemic shunt diameter
| Characteristics | Shunt diameter |
| ||
|---|---|---|---|---|
| ≤10 mm | 11–20 mm | >20 mm | ||
|
|
|
| ||
| Age: ≥65 years, | 4 (50%) | 13 (62%) | 1 (20%) | 0.466 |
| Sex: Male, | 3 (38%) | 10 (48%) | 5 (100%) | 0.049 |
| Alcohol: Yes, | 0 (0%) | 3 (14%) | 4 (80%) | 0.008 |
| Alb: ≥2.5 g/dL, | 8 (100%) | 17 (81%) | 2 (40%) | 0.013 |
| T.Bil: ≥2 mg/dL, | 1 (12%) | 2 (10%) | 2 (40%) | 0.279 |
| PT: ≥70%, | 4 (50%) | 5 (24%) | 0 (0%) | 0.042 |
| Encephalopathy: Yes, | 2 (25%) | 9 (43%) | 5 (100%) | 0.015 |
| NH3: ≥110 μg/dL, | 0 (0%) | 7 (44%) | 4 (80%) | 0.007 |
| Ascites: Yes | 3 (38%) | 9 (43%) | 3 (60%) | 0.464 |
| Indication (HE/GV) | 2/6 | 9/21 | 5/0 | 0.002 |
| Child–Pugh A, | 3 (38%) | 4 (19%) | 0 (0%) | 0.099 |
| HCC History, | 3 (38%) | 11 (52%) | 1 (20%) | 0.745 |
| FIB‐4: >5, | 6 (75%) | 15 (71%) | 3 (60%) | 0.271 |
P < 0.05,
P < 0.01.
FIB‐4, fibrosis index based on four factors; GV, gastric varices; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; HVPG, hepatic venous pressure gradient.
Figure 2Associations between spontaneous portosystemic shunt (SPSS) diameter and baseline clinical parameters of albumin (Alb), prothrombin time (PT, %), total bilirubin, and NH3 prior to balloon‐occluded retrograde transvenous obliteration. A larger shunt diameter was observed in males (P = 0.049), albumin <2.5 g/dL (P = 0.013), PT% <70% (P = 0.042), and NH3 ≥110 μg/dL (P = 0.007). *P < 0.05, **P < 0.01.
Figure 3Association between spontaneous portosystemic shunt (SPSS) diameter and the changes in clinical parameters of hepatic venous pressure gradient (HVPG), albumin, total bilirubin, prothrombin time (PT, %), and NH3 6 months after balloon‐occluded retrograde transvenous obliteration. (a) It is seen that HVPG had a tendency to decrease with a large SPSS shunt diameter. (b) It is seen that HVPG had a tendency to increase after balloon occlusion with a large SPSS diameter. (c) It is seen that the SPSS diameter was significantly correlated with ΔHVPG. *P < 0.05, **P < 0.01.
Figure 4Association between spontaneous portosystemic shunt (SPSS) diameter and clinical parameters of albumin, prothrombin time (PT, %), total bilirubin, and NH3 prior to and 6 months after balloon‐occluded retrograde transvenous obliteration (a) in all patients, (b) in patients with Child–Pugh (CP) A/B, and (c) in patients with CP C. *P < 0.05, **P < 0.01.